Navigation Links
Prednisolone not benficial in most cases of community-acquired pneumonia
Date:2/23/2010

Patients hospitalized with mild to moderate community-acquired pneumonia (CAP) should not be routinely prescribed prednisolone, a corticosteroid, as it is associated with a recurrence of symptoms after its withdrawal, according to the first randomized double-blind clinical trial to address the subject.

"Prednisolone therapy next to antibiotic therapy in patients hospitalized with CAP should not be recommend due to lack of clincial benefit and a higher rate of late failures," said Dominic Snijders, M.D., lead author on the study and at the Medical Centre Alkmaar in the Netherlands.

The findings have been published online ahead of print publication in the American Thoracic Society's American Journal of Respiratory and Critical Care Medicine.

To assess the efficacy of prednisolone therapy along with standard doctor-managed care for patients admitted to the hospital with CAP, Dr. Snijders and colleagues prospectively enrolled 213 patients who had been hospitalized with CAP and randomly assigned them to receive the usual antibiotic therapy as prescribed by their physicians supplemented with either prednisolone (40 mg dose once daily) or placebo for a week.

They found that patients on prednisolone recovered more rapidly from their fevers and had a more rapid decline in their c-reactive protein (CRP) levels than patients on placebo, indicating decreased inflammation. However, after 14 days, the patients in the prednisolone group had higher levels of CRP than the patients in the placebo group. Furthermore, three times as many patients in the prednisolone group had "late failure," defined as the recurrence of symptoms more than 72 hours after initial therapeutic success, and these patients were almost four times as likely to require additional antibiotic treatment than patients with late failure in the placebo group (6.7 percent versus 1.8 percent).

"Our study clearly shows that prednisolone therapy does not have a place in patients with CAP," said Dr. Snijders. However, he pointed out, in some cases such as when CAP is severe or occurs in conjunction with COPD, there is not enough information to draw a conclusion. Previous studies have found benefit of corticosteroid therapy among patients with severe CAP. Studies with patients with CAP and COPD have also indicated the possibility of a protective effect of prednisolone, but there have been no controlled trials.

Dr. Snijders suggested that the association of prednisolone therapy in CAP with late failures may be due to a rebound effect that could be precipitated by the abrupt withdrawal of the therapy. "Non-survivors on corticosteroid therapy died later than non-survivors without corticosteroids, respectively 13.8 versus 7.1 days," he wrote. "A tapering of the corticosteroids might protect against the rebound of inflammation."

"Further trials are indeed needed in patients with severe CAP," said Dr. Snijders. "Also, more information is needed about COPD patients, corticosteroids and pneumonia. Possible future intervention could be monoclonal TNF-alpha-antibodies or specific antibodies against other key mediators in the inflammation response. We are considering further studies in these directions."


'/>"/>

Contact: Keely Savoie
ksavoie@thoracic.org
212-315-8620
American Thoracic Society
Source:Eurekalert

Related medicine news :

1. RAND finds cases of undiagnosed diabetes drop sharply
2. South Texas Doctors Report More Severe Cases of Community Staph Super Bug Hospitalizing Children
3. Gene profiling can single out the worst cases of multiple myeloma and guide therapy
4. Peer-Reviewed, Online Database Showcases Local, County and State Pandemic Planning
5. HIV/AIDS Cases Among State and Federal Prison Inmates Fell for the Sixth Straight Year During 2005
6. Surge in U.S. Cases of Rocky Mountain Spotted Fever
7. The era of global aging: GSA showcases cutting-edge San Francisco meeting topics
8. Capsule endoscopy turning up undiagnosed cases of Crohns disease
9. BancTec Showcases Accounts Payable and Healthcare Solutions at The Association for Financial Professionals (AFP) Annual Conference
10. Stereotaxis Showcases Interventional Cardiology Capabilities of Niobe Magnetic Navigation System
11. Stereotaxis Highlights Live Coronary and Peripheral Vascular Cases Performed at TCT With Stereotaxis Magnetic Navigation System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... PA (PRWEB) , ... December 02, 2016 , ... ... and pharmaceutical organizations to build intelligent, connected applications, was named the best Sales ... , The winner announcement was made today by the Software & Information ...
(Date:12/2/2016)... ... December 02, 2016 , ... ‘Tis the season for giving! Today, 20 ... the National Family Partnership and the Drug Enforcement Administration as part of the National ... the 10 winning schools who decorated their campuses with this year’s Red Ribbon Week ...
(Date:11/30/2016)... Northridge, CA (PRWEB) , ... November 30, 2016 ... ... Elyson, announce that they now offer a comprehensive in-house dental plan for all ... dentists have developed a plan that gives patients a number of perks, including ...
(Date:11/30/2016)... PALMYRA, Wisconsin (PRWEB) , ... November 30, 2016 ... ... inclusion in the 2016 Deloitte Wisconsin 75, an annual ranking and recognition of ... consecutive year on the list, having ranked from 2008-2016. In addition, Standard Process ...
(Date:11/30/2016)... Chino Hills, CA (PRWEB) , ... November 30, ... ... in eating disorder and mental health treatment has announced the opening of a ... specialized residential treatment for girls with mental health issues such as severe anxiety, ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... FRANCISCO , Dec. 2, 2016  PipelineRx, a ... telepharmacy, will be offering demonstrations of its SaaS-based ... Society of Health-System Pharmacists 2016 Midyear Clinical Meeting ... Vegas . With nearly 300 hospital clients ... services and technology designed to dramatically improve pharmacy ...
(Date:12/2/2016)... December 2, 2016 On Thursday, ... honored excellence in research, development and innovation in the ... dinner was held in the presence of Sergey Tsyb, ... Russian Federation , Natalia Sanina, First Vice ... Murashko , Head of Roszdravnadzor, National Service of Control ...
(Date:12/2/2016)...  Eli Lilly and Company (NYSE: LLY ... provide updated financial guidance for 2016 on Thursday, December ... on that day with the investment community and media ... The conference call will begin at 10 a.m. ET. ... live webcast of the conference call through a link ...
Breaking Medicine Technology: